Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-002060

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
James Patrick Kelly
Officer — EVP & Chief Financial Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Jan 2, 2018M5,000—A144,721D
Common StockF2,F4Jan 2, 2018M5,000—A154,721D
Common StockF2,F4Jan 2, 2018M7,500—A177,221D
Common StockF7Jan 2, 2018S9,155$15.3461D168,066D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitF2,F8,F9—Jan 2, 2018M5,000D——Common Stock5,0000D
Restricted Stock UnitF2,F10,F9—Jan 2, 2018M5,000D——Common Stock5,0005,000D
Restricted Stock UnitF2,F11,F9—Jan 2, 2018M7,500D——Common Stock7,50015,000D

Explanation of responses